Jump to content
RemedySpot.com

Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in HBeAg-Negative Chronic Hepatitis B

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Dec 5. [Epub ahead of print]

Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in

HBeAg-Negative Chronic Hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP,

Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

Division of Internal Medicine, Athens University Medical School, Athens, Greece.

Abstract

BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the

appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV)

replication parameters is not known, inasmuch as integrated sequences of HBV-DNA

may also contribute to its serum levels, especially in HBeAg-negative chronic

hepatitis B (CHB) patients.

METHODS: We investigated HBsAg serum levels, its hepatocellular expression and

their relationship to HBV replicative- and host-response parameters before

treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3

months of virological response on oral antiviral (NUC) therapy also. Liver

cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed

in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were

measured in samples drawn on the day of liver biopsy

RESULTS: In untreated patients, serum HBsAg correlated positively with

HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but

not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA

correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum

HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy

decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4%

(P=0.026) in paired comparisons and, as expected, significantly decreased serum

HBV-DNA and ALT levels, but not cccDNA.

CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver

HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely

dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years

significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA.

European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21145875 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 5. [Epub ahead of print]

Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in

HBeAg-Negative Chronic Hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP,

Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

Division of Internal Medicine, Athens University Medical School, Athens, Greece.

Abstract

BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the

appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV)

replication parameters is not known, inasmuch as integrated sequences of HBV-DNA

may also contribute to its serum levels, especially in HBeAg-negative chronic

hepatitis B (CHB) patients.

METHODS: We investigated HBsAg serum levels, its hepatocellular expression and

their relationship to HBV replicative- and host-response parameters before

treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3

months of virological response on oral antiviral (NUC) therapy also. Liver

cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed

in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were

measured in samples drawn on the day of liver biopsy

RESULTS: In untreated patients, serum HBsAg correlated positively with

HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but

not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA

correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum

HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy

decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4%

(P=0.026) in paired comparisons and, as expected, significantly decreased serum

HBV-DNA and ALT levels, but not cccDNA.

CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver

HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely

dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years

significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA.

European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21145875 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 5. [Epub ahead of print]

Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in

HBeAg-Negative Chronic Hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP,

Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

Division of Internal Medicine, Athens University Medical School, Athens, Greece.

Abstract

BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the

appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV)

replication parameters is not known, inasmuch as integrated sequences of HBV-DNA

may also contribute to its serum levels, especially in HBeAg-negative chronic

hepatitis B (CHB) patients.

METHODS: We investigated HBsAg serum levels, its hepatocellular expression and

their relationship to HBV replicative- and host-response parameters before

treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3

months of virological response on oral antiviral (NUC) therapy also. Liver

cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed

in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were

measured in samples drawn on the day of liver biopsy

RESULTS: In untreated patients, serum HBsAg correlated positively with

HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but

not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA

correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum

HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy

decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4%

(P=0.026) in paired comparisons and, as expected, significantly decreased serum

HBV-DNA and ALT levels, but not cccDNA.

CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver

HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely

dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years

significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA.

European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21145875 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 5. [Epub ahead of print]

Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in

HBeAg-Negative Chronic Hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP,

Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

Division of Internal Medicine, Athens University Medical School, Athens, Greece.

Abstract

BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the

appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV)

replication parameters is not known, inasmuch as integrated sequences of HBV-DNA

may also contribute to its serum levels, especially in HBeAg-negative chronic

hepatitis B (CHB) patients.

METHODS: We investigated HBsAg serum levels, its hepatocellular expression and

their relationship to HBV replicative- and host-response parameters before

treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3

months of virological response on oral antiviral (NUC) therapy also. Liver

cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed

in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were

measured in samples drawn on the day of liver biopsy

RESULTS: In untreated patients, serum HBsAg correlated positively with

HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but

not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA

correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum

HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy

decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4%

(P=0.026) in paired comparisons and, as expected, significantly decreased serum

HBV-DNA and ALT levels, but not cccDNA.

CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver

HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely

dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years

significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA.

European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21145875 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...